Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances

被引：1

作者：

Chen, Mei-Kuang ^{[1
]}

Xia, Weiya ^{[1
]}

Dong, Qiongzhu ^{[2
]}

Du, Yi ^{[3
]}

Wang, Hung-Ling ^{[4
]}

Tapia, Coya ^{[1
]}

Wei, Yongkun ^{[1
]}

Han, Ye ^{[5
]}

Chu, Yu-Yi ^{[1
]}

Yam, Clinton ^{[1
]}

Gao, Yuan ^{[1
]}

Wang, Yu-Han ^{[1
]}

Meric-Bernstam, Funda ^{[1
]}

Liu, Jinsong ^{[1
]}

Wang, Shao-Chun ^{[4
]}

Yu, Dihua ^{[1
]}

Hung, Mien-Chie ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Fudan Univ, Shanghai, Peoples R China

[3] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA

[4] China Med Univ, Taichung, Taiwan

[5] China Med Univ, Affiliated Shengjing Hosp, Shenyang, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-5682

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5682

引用

页数：2

共 50 条

[1] PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer
Chen, Yu
Fan, Xudong
Lu, Ruohuang
Zeng, Shan
Gan, Pingping
[J]. GENES AND IMMUNITY, 2024, 25 (04) : 307 - 316
[2] PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
D'Andrea, Alan
[J]. ONCOLOGIST, 2017, 22 : S1 - S1
[3] Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells
Han, Ye
Chen, Mei-Kuang
Wang, Hung-Ling
Hsu, Jennifer L.
Li, Chia-Wei
Chu, Yu-Yi
Liu, Chun-Xiao
Nie, Lei
Chan, Li-Chuan
Yam, Clinton
Wang, Shao-Chun
He, Gui-Jin
Hortobagyi, Gabriel N.
Tan, Xiao-Dong
Hung, Mien-Chie
[J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (03): : 608 - +
[4] PARP inhibitor resistance and acquired vulnerability in breast cancer.
D'Andrea, Alan D.
[J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 19 - 20
[5] PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes
Yu, Tony
Lok, Benjamin H.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024,
[6] PARP inhibitor response in prostate cancer
Louise Stone
[J]. Nature Reviews Urology, 2023, 20 : 130 - 130
[7] PARP inhibitor combinations in prostate cancer
Pezaro, Carmel
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[8] PARP inhibitor response in prostate cancer
Stone, Louise
[J]. NATURE REVIEWS UROLOGY, 2023, 20 (3) : 130 - 130
[9] PARP inhibitor nanotherapy for ovarian cancer
Baldwin, Paige
Ohman, Anders
Thong, Jeremy
Tangutoori, Shifalika
Dinulescu, Daniela
Sridhar, Srinivas
[J]. CLINICAL CANCER RESEARCH, 2016, 22
[10] Combining PARP inhibitor with TACC3 inhibition overcomes PARP inhibitor resistance in ovarian cancer
Wu, Yu
Wang, Qilong
Deng, Chaolin
Li, Mo
Xiao, Yinan
[J]. CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →